Laura Kulik

Laura Kulik

Auto-generated profile, based on publicly available information

Laura Kulik

Department of Gastroenterology and Hepatology, Northwestern University, Chicago, IL

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Gastroenterology
Verified
Journal Article
Open access
PDF file
RSRiad Salem
Riad Salem
RLRobert J. Lewandowski
Robert J. Lewandowski
MMMary F. Mulcahy
Mary F. Mulcahy
ARAhsun Riaz
Ahsun Riaz
RRRobert K. Ryu
Robert K. Ryu
LKLaura Kulik
Laura Kulik
Hepatocellular carcinoma (HCC) has limited treatment options; long-term outcomes following intra-arterial radiation are unknown. We assessed clinical outcomes of patients treated with intra-arterial yttrium-90 microspheres (Y90). Patients with HCC (n = 291) were treated with Y90 as part of a single-center, prospective, longitudinal cohort study. Toxicities were recorded using the Common Terminology Criteria version 3.0. Response rate and time to progression (TTP) were determined using World Health Organization (WHO) and European Association for the Study of the Liver (EASL) guidelines. Survival by stage was assessed. Univariate/multivariate analyses were performed. A total of 526 treatments were administered (mean, 1.8; range, 1–5). Toxicities included fatigue (57%), pain (23%), and nausea/vomiting (20%); 19% exhibited grade 3/4 bilirubin toxicity. The 30-day mortality rate was 3%. Response rates were 42% and 57% based on WHO and EASL criteria, respectively. The overall TTP was 7.9 months (95% confidence interval, 6–10.3). Survival times differed between patients with Child–Pugh A and B disease (A, 17.2 months; B, 7.7 months; P = .002). Patients with Child–Pugh B disease who had portal vein thrombosis (PVT) survived 5.6 months (95% confidence interval, 4.5–6.7). Baseline age; sex; performance status; presence of portal hypertension; tumor distribution; levels of bilirubin, albumin, and α-fetoprotein; and WHO/EASL response rate predicted survival. Patients with Child–Pugh A disease, with or without PVT, benefited most from treatment. Patients with Child–Pugh B disease who had PVT had poor outcomes. TTP and overall survival varied by patient stage at baseline. These data can be used to design future Y90 trials and to describe Y90 as a potential treatment option for patients with HCC.

20 September 2012 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
LKL. M. Kulik
L. M. Kulik
RFR. A. Fisher
R. A. Fisher
DRD. R. Rodrigo
D. R. Rodrigo
JBJr. R. S. Brown
Jr. R. S. Brown
CFC. E. Freise
C. E. Freise
TGthe A2ALL Study Group
the A2ALL Study Group
Hepatocellular carcinoma (HCC) represents an increasing fraction of liver transplant indications; the role of living donor liver transplant (LDLT) remains unclear. In the Adult‐to‐Adult Living Donor Liver Transplantation Cohort Study, patients with HCC and an LDLT or deceased donor liver transplant (DDLT) for which at least one potential living donor had been evaluated were compared for recurrence and posttransplant mortality rates. Mortality from date of evaluation of each recipient's first potential living donor was also analyzed. Unadjusted 5‐year HCC recurrence was significantly higher after LDLT (38%) than DDLT (11%), (p = 0.0004). After adjustment for tumor characteristics, HCC recurrence remained significantly different between LDLT and DDLT recipients (hazard ratio (HR) = 2.35; p = 0.04) for the overall cohort but not for recipients transplanted following the introduction of MELD prioritization. Five‐year posttransplant survival was similar in LDLT and DDLT recipients from time of transplant (HR = 1.32; p = 0.27) and from date of LDLT evaluation (HR = 0.73; p = 0.36). We conclude that the higher recurrence observed after LDLT is likely due to differences in tumor characteristics, pretransplant HCC management and waiting time.

1 February 2015 in Clinics in Liver Disease
Verified
Journal Article
Closed access
LKLaura M. Kulik
Laura M. Kulik
ACAttasit Chokechanachaisakul
Attasit Chokechanachaisakul

31 December 2009 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
RLRobert J. Lewandowski
Robert J. Lewandowski
ARAhsun Riaz
Ahsun Riaz
RRRobert K. Ryu
Robert K. Ryu
MMMary F. Mulcahy
Mary F. Mulcahy
KSKent T. Sato
Kent T. Sato
RSRiad Salem
Riad Salem

1 November 2012
Verified
Journal Article
Closed access
BNBeatrice Nardone
Beatrice Nardone
JHJennifer R Hensley
Jennifer R Hensley
LKLaura Kulik
Laura Kulik
DWDennis P West
Dennis P West
MMMary Mulcahy
Mary Mulcahy
MLMario E Lacouture
Mario E Lacouture

1 August 2014 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
MPMeena A. Prasad
Meena A. Prasad
LKLaura M. Kulik
Laura M. Kulik
Orthotopic liver transplantation (OLT) offers the best chance for cure in the setting of unresectable hepatocellular carcinoma (HCC). A consensus statement recommends locoregional therapy (LRT) be considered in patients with HCC who are expected to wait more than 6 months for OLT to diminish dropout from the waiting list because of tumor progression. This article reviews LRT as a bridge to OLT in patients with HCC.